beinaglutide vs semaglutide GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis Efficacy and safety of incretin

In an 8-week study using low-dose liraglutide (0.6 mg/day) in patients with type 2 diabetes no weight or fat loss was produced, but both fasting and postprandial glucose were substantially reduced, but neither fasting nor postprandial insulin (or C-peptide) response was increased [19]

At Week 48, 95.7 percent achieved a weight loss of greater than or equal to five percent, with 87 percent achieving this level to 10, 47.8 percent 20 percent, and 26.1 percent 30 percent

Abstracts are published in Diabetic Medicine

Consult Healthcare Providers: Alcohol Guidelines for GLP-1 Users Seeking guidance from healthcare professionals is essential for individuals using GLP-1 treatments in relation to alcohol and GLP-1 consumption